Research programme: Gram negative infection therapeutics - NosopharmAlternative Names: NOSO 95; NOSO 95179; NOSO 95400
Latest Information Update: 13 Jan 2016
At a glance
- Originator Nosopharm
- Mechanism of Action Bacterial growth inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gram-negative infections